Kornimate/medical-research-clean huggingface dataset:
hair transplantation in cicatricial alopecia

Conditions: Hair Transplantation; Cicatricial Alopecia

Summary: follicular unit extraction as a method of hair transplantation in cicatricial alopecia

the study will include 20 patients with cicatrical alopecia.patients will be randomly assigned into two groups:group (a):include ten patients will undergo (fue) alone. group (b): include ten patients will undergo(fue) and (prp).3-surgical technique: * preoperative investigations including complete blood count, coagulation profile and hepatitis viral markers. 1-group(a): will undergo (fue) * washing the scalp with antiseptic shampoo before the procedure. * tumuscentanaesthesia:the donor area is anesthetized with a lidocaine 1% solution diluted with 20 cc saline in addition to adrenaline. * creation of micropunches(0.7-1 mm) using micromotor. * after removal of the punch,the follicular unit is extracted with jweler's forceps. * extracted grafts are then placed on chilled saline gauze for maximum four hours until ready for transplantation. * the recipient area is prepared with rectangular scalpel blades 1mm or hypodermic blades 0.9 mm. * implantation using fine tipped jweler's forceps. * finally, receptor and donor areas will be softly cleansed with saline and crepe bandage is applied. 2-group (b): fue+prp * the same procedure will be done but grafts will be placed in prp solution. * prp session one week before transplantation then monthly for 3 monthes after (fue). * preparation of prp * 10 cc blood will be aspirated in test tube contained a modified solution of anticoagulant,called acid-citrate-dextrose type (acda), in which the physiological ph will reached to preserve the platelet integrity. * the first spin of whole blood sample will be at 2500 rpm for 4 minutes * the second spin at 4000 for 20 minutes for obtained plasma. * platelets are separated as a pellet at the bottom of the tube from platelet-poor plasma (ppp) above. the platelet-rich pellet is resuspended in remaining amount of plasma. the resulting suspension is used as prp. * prp is injected in the recipient area. 4-follow up: * follow up clinically by digital photographs and trichoscopy 1 week after operation, after 3 months and after 6 months.

Eligibility criteria:
inclusion criteria: * • patients with unacceptable visible scarring alopecia. * adequate donor area. * patient free of signs of disease activity evidenced by trichoscopy. * patients having inadequate laxity for a strip excision (too tight skin). * when previous scars of strip surgeries make further strips impossible. exclusion criteria: * • inadequate donor area. * signs of active disease or infection. * patient who is not willing for long sessions for several hours or multiple sessions as needed due to the slowness of the process * contraindications for surgical procedure as bleeding tendency. * contraindications for prp as (cardiovascular, autoimmune disorders, hematological disorders and neoplasms).

Keywords: hair loss, follicuular unit extraction, platelet rich plasma
virtual reality (vr) to reduce preoperative anxiety.

Conditions: Preoperative

Summary: most patients awaiting surgery show significant anxiety score which can be influenced by the fear of anesthesia or surgery but also by the context of care. these anxious patients will have more postoperative complications and can also develop chronic pain. the virtual reality aqua module induces hypnosis and is specially designed to reduce anxiety. the purpose of the study is to examine the effect of a virtual reality session on preoperative anxiety.


Eligibility criteria:
inclusion criteria: * patients undergoing scheduled orthopedic surgery with loco-regional anesthesia at saint-luc hospital. * patients not following long-term psychotherapeutic treatment * patients not taking psychotropic medication * free, informed and written consent signed by the investigator and the patient before the procedure. exclusion criteria: * patient not speaking french * patients with long-term psychotherapeutic treatment * patients taking psychotropic drugs * patient blind and deaf
a study to evaluate the efficacy and safety of ccx282-b in subjects with moderate to severe crohn's disease

Conditions: Crohn's Disease

Summary: the purpose of this study is to determine whether ccx282-b is effective in treating patients with moderate to severe crohn's disease.

study acquired by amgen and all disclosures were done by previous sponsor chemocentryx.

Eligibility criteria:
key inclusion criteria: * moderate to severe crohn's disease * cdai 250-450 * crp \>7.5 * signed written informed consent key exclusion criteria: * \> 100 cm of small bowel resected * ileostomy, colostomy or rectal pouch * diagnosis of ulcerative colitis or indeterminate colitis * evidence of short bowel syndrome requiring enteral or parenteral supplementation or total parenteral nutrition * hepatitis b, c or hiv infection * history of infection requiring iv antibiotics * serious or gi infection in the previous 12 weeks

Keywords: double-blind placebo-controlled multicenter efficacy safety
collecting and storing blood and tumor tissue samples from patients undergoing prostatectomy or transurethral resection of the prostate

Conditions: Prostate Cancer

Summary: the primary objective of this study is to collect material for study's to assess mechanisms of tumor progression, mechanisms of resistance, isolation of stem cells and biologic markers in tissue, serum and peripheral blood mononuclear cells.


Eligibility criteria:
disease characteristics: * undergoing routine prostatectomy or transurethral resection of the prostate (turp) patient characteristics: 5.1.1 patient is undergoing routine prostatectomy or turp. 5.1.2 patient is ≥ 18 years old. 5.1.3 patient must give informed consent. prior concurrent therapy: * see disease characteristics

Keywords: prostate cancer
does covid-19 pandemic reduce in-hospital mortality?

Conditions: Covid19; In-hospital Cardiac Arrest

Summary: covid-19, which emerged in china in december 2019, has become a pandemic with its spread to many countries of the world. although it is suggested that hospital admissions are reduced due to some reasons such as trauma, during covid-19 pandemic, it is controversial whether in-hospital mortality rates changed. therefore this multi-centered study aimed to determine how in-hospital mortality effected during the pandemic period according to the specific patient groups.

covid-19, which emerged in china in december 2019, has become a pandemic with its spread to many countries of the world. although it is suggested that hospital admissions are reduced due to some reasons such as trauma, during covid-19 pandemic, it is controversial whether in-hospital mortality rates changed. therefore this multi-centered study aimed to determine how in-hospital mortality effected during the pandemic period according to the specific patient groups. thus, in case of a pandemic, it will be a guide in which patient groups healthcare providers should be more careful about.

Eligibility criteria:
inclusion criteria: * deaths, with all required data available, occurred within the study hospitals * centers accepted to participate with an informed consent exclusion criteria: * lack of consent * lack of data * deaths occurred outside the study hospitals
endostatin serum levels during bicycle stress test

Conditions: Smoking; Cardiac Diseases

Summary: endostatin, a 20-kda cleavage product of collagen xviii, is a component of the extracellular matrix expressed in the basement membrane. as a potent inhibitor of angiogenesis, endostatin induces endothelial cell apoptosis and diminishes cell migration, adhesion and proliferation. endostatin may stop the progression of atherosclerosis. atherosclerotic heart disease involves unwanted tissue growth. by cutting off the blood supply from a plaque the likelihood of plaque rupture may eventually be reduced. recent data indicates that the loss of collagen xviii/endostatin is related to the enhancement of neo-vascularization and vascular permeability in atherosclerosis. plaque neo-vascularization strongly correlates with the regional content of inflammatory cells. furthermore, increased vascular permeability enhances lipid accumulation in the vessel walls, hence increasing foam cells. therapeutic angiogenesis is a most promising strategy for the treatment of myocardial infarction. however, it remains unknown if and how endogenous angiogenesis inhibitors, such as endostatin, regulate angiogenesis in myocardial infarction. rat models showed that after myocardial infarction endostatin neutralization displayed adverse left ventricular remodeling and severe heart failure compared with controls. although angiogenesis was increased, tissue remodeling and interstitial fibrosis were further exaggerated in post-myocardial infarction hearts by endostatin neutralization. however, several studies suggest that endostatin may locally modulate coronary collateral formation by inhibiting collateral vessel formation in patients with ischemic heart disease. during treadmill exercise tests in healthy volunteers a significant increase in circulating endostatin levels can be observed. exercise induces angiogenesis in cardiac and skeletal muscles by decreasing endostatin in the muscle tissues to increase blood flow to these metabolically active tissues. thereby endostatin is released into the general circulation. in summary, endostatin might be a new weapon to fight against atherosclerotic progression by inhibiting neo-vascularization of atherosclerotic plaques.


Eligibility criteria:
inclusion criteria: * smoking/non smoking * healthy/non healthy (if for cmp, chd study) * age (depending on the group affiliation) exclusion criteria: * suffering from grave diseases
clinical performance and reproducibility of the accelerate phenotest™ blood culture (bc) kit with new antibiotic wave i updates

Conditions: Bacteremia

Summary: this is a performance and reproducibility study to validate new or updated antimicrobials on the accelerate phenotest™ bc kit. the data from this study will be used to support the submission to the fda for clearance in the us and for global registrations of the device intended for in vitro diagnostic use.

this clinical study entitled "clinical performance and reproducibility of the accelerate phenotest™ bc kit using the accelerate pheno™ system with new antibiotic wave i updates for antimicrobial susceptibility testing of positive blood culture specimens" is designed to demonstrate the clinical performance and reproducibility of the new or updated antimicrobials on the accelerate phenotest™ bc kit, which was previously fda-cleared in february 2017. clinical performance and reproducibility evaluations will be conducted at a minimum of three sites to determine the clinical performance of the new or updated antimicrobials from a combination of fresh (de-identified, remnant specimens) and contrived positive blood culture samples, to include at least 375 total specimens. the study sites selected will have expertise in blood culture diagnostics and will be able to conduct the study in accordance with this protocol and good clinical practices (gcp). additionally, prior to study initiation, each site will have approval from the local institutional review board (irb). it is anticipated that the data from this study will be used to support the submission to the fda for clearance in the us and for global registrations of the device intended for in vitro diagnostic use.

Eligibility criteria:
inclusion criteria: * blood culture positivity is ≤ 8 hours prior to initiation of testing with the accelerate pheno™ system * positive blood culture sample containing gram-negative rods according to gram stain results * for fresh specimens, de-identified, remnant positive blood culture specimens from patients for which standard of care (soc) testing has been initiated and the remaining samples would otherwise be discarded * a minimum sample volume of 2.0 ml * seeded blood culture specimens derived from archived bacterial exclusion criteria: * blood culture positivity is \> 8 hours prior to initiation of testing with the accelerate pheno™ system * insufficient (less than 2.0 ml) remnant sample volume * from a patient that has already been enrolled in the study * fresh samples from mycobacterial-type blood culture media (bactec™ myco/f lytic, bact/alert® mp bottle, versatrek® myco) or charcoal-containing media * seeded specimens that appear mixed (by gram stain or purity plating) after bottle culture positivity

Keywords: positive blood culture
prognostic factors , morbidity and mortality in patients with neuromuscular disorders admitted in icu

Conditions: Muscular Dystrophies; Intensive Care (ICU) Myopathy

Summary: muscular dystrophies are neuromuscular disorders with disability. restrictive pulmonary failure and cardiomyopathy affect prognosis.the investigators aim to establish predictive factors for mortality and morbidity in intensive care unit (icu ) and to describe the long term follow up after icu discharge.

muscular dystrophies are neuromuscular disorders with disability. restrictive pulmonary failure and cardiomyopathy affect prognosis. little is known about morbidity and mortality of patients with muscular dystrophies admitted in intensive care unit (icu).the investigators aim to describe the spectrum of patients with muscular dystrophies admitted in icu , to establish predictive factors for icu mortality and morbidity and to describe the long term follow up after icu discharge.

Eligibility criteria:
inclusion criteria: * admitted in icu * duchenne muscular dystrophy * becker muscular dystrophy * lgmd * steinert disease * pompe disease * fshd * metabolic disease * mitochondrial disease * congenital myopathy * others neuro-muscular diseases exclusion criteria: * brain injury * minor patient

Keywords: intensive care unit muscular dystrophy mortality prognosis tracheostomy
injured spinal cord pressure evaluation

Conditions: Spinal Cord Injuries

Summary: about a thousand people a year in the united kingdom survive a spinal cord injury but are left paralysed or wheelchair-bound. the annual cost of care for spinal cord injury victims is more than half a billion pounds. we propose that after spinal cord injury, cord pressure at the injury site rises, damaging the spinal cord further by secondary ischaemia. the value of measuring and reducing cord pressure after spinal cord injury is unknown. the injured spinal cord is compressed by bone malalignment and cord swelling. current management involves realigning and fixing the bony fragments using metal screws, rods and plates. we hypothesise that: 1. bony realignment alone does not adequately decompress the swollen cord, which remains compressed against the surrounding dura. 2. that duraplasty reduces intra spinal pressure more effectively than bone realignment alone. 3. localised hypothermia reduces intra spinal pressure and improves metabolism. we will develop a novel method to measure cord pressure and metabolism at the injury site after spinal cord injury and determine whether the cord pressure rises, for how long, and with what impact on spinal cord metabolism. this is a pilot study to find out whether spinal cord pressure and metabolism can be measured after spinal cord injury and whether they are effected by treatment choices. we will examine if spinal cord perfusion pressure correlates with clinical outcomes.


Eligibility criteria:
inclusion criteria: diagnosis of traumatic spinal cord injury american spinal injuries association grade a-c spinal cord injury presents within 72hrs of injury capacity to consent for study exclusion criteria: concurrent major co-morbidity likely to influence outcome other major concurrent injury likely to influence outcome

Keywords: intra spinal pressure spinal cord perfusion pressure microdialysis duroplasty
intergenerational transmission of traumatic stress

Conditions: Stress, Psychological; Stress Disorders, Traumatic; Emotion Regulation; Behavior, Child; Emotional Stress; Trauma, Psychological; Anxiety; Depression; Coping Skills; Parent-Child Relations; Parenting

Summary: millions of u.s. parents have experienced trauma, putting them at risk for maladaptive parenting practices, which then confer vulnerabilities to their children. this study aims to enhance understanding of how parental emotional dysregulation associated with traumatic stress impedes effective parenting. the study employs neurophysiological methods (electroencephalogram; eeg) to address some of the challenges inherent in the study of emotion (particularly in trauma-exposed individuals) and to identify potential biomarkers of traumatic stress and response to intervention.

this research study consists of a randomized controlled trial of 60 families of preschool-aged children in which a parent/caregiver has their own history of childhood interpersonal trauma or loss. parent/caregiver participants and their preschool-aged child will participate in two phases of assessment (baseline/time 1 and follow-up/time 2). each phase of assessment will include parent/caregiver participant completion of self-report questionnaire measures, a parent-child interaction task (which will be video-recorded for later behavioral coding) and a parent eeg assessment. after the time 1 (t1) assessments, participants will be randomized to either the focus-early childhood program group (n = 30; experimental group) or the parent education curriculum website group (n = 30; active comparator group). the t2 assessment phase will begin at 3-months post-baseline. the focus-ec program is an 8-week program, so families should have completed the program by 3 months post-baseline. in the event that a family that was randomized to the focus-ec program group has not completed the program by the 3-month mark, the t2 assessment will be initiated once the program has been completed (up to 6 months post-baseline).

Eligibility criteria:
inclusion criteria: * parent/caregiver (must be legal guardian) of a 3- to 6-year-old child * child must cohabitate with the parent/caregiver * parent/caregiver participant must have experienced some form of interpersonal trauma during their own childhood (e.g., abuse, neglect, witnessing domestic violence) * parent/caregiver must be english-speaking * parent/caregiver must have access to internet and webcam exclusion criteria: * does not meet inclusion criteria * parent/legal guardian does not want the child to participate in the study * significant neurological disorder (included in pre-screening protocol) * active psychosis/mania (as assessed by staff) * significant child developmental delays (as assessed by staff) families excluded from the study will be provided with a list of online and/or community resources.

Keywords: resilience families parents children preschooler intervention
the effect of neutral peritoneal dialysis (pd) solution with minimal glucose-degradation-product (gdp) on fluid status and body composition

Conditions: Renal Failure; ESRD; Cardiovascular Disease

Summary: chronic utilization of bio-incompatible peritoneal dialysis (pd) solution has been implicated as a cause of progressive loss of peritoneal permeability and recurrent fluid overload in pd patients. previous studies show that pd solution with neutral ph and low gdp resulted in a superior profile of pd effluent mesothelial cell marker and a lower degree of systemic inflammation as compared to conventional pd solution. the investigators propose a prospective randomized control study to compare the arterial stiffness, nutrition and body fluid status between pd patients treated with conventional solution and those with neutral ph low gdp solution. the investigators plan to study 100 new pd patients. they will be randomized to be treated with neutral ph low gdp solution or conventional solution. all patients will be followed for 52 weeks. in addition to routine clinical measurements, the investigators will measure their body water composition by bioimpedance spectroscopic method, arterial pulse wave velocity by pressure transduction method, as well as radiographic parameters of intravascular volume status, based on the routine chest radiograph. the study would help to define the clinical benefit of biocompatible pd solution.

(see above)

Eligibility criteria:
inclusion criteria: * new adult continuous ambulatory peritoneal dialysis (capd) patients, both diabetic and non-diabetic exclusion criteria: * unlikely to survive, planned to have elective living-related kidney transplant, or transfer to other renal center within 6 months

Keywords: malnutrition fluid status survival
4scar19u t cells targeting b cell malignancies

Conditions: B Cell Malignancies

Summary: the purpose of this study is to assess the feasibility, safety and efficacy of universal car t cell therapy against cd19-positive hematological malignancies using a novel cd19-specific car t cell product, 4scar19u t cells. the study also aims to learn more about the function of the 4scar19u t cells and their persistence in patients. this is a phase i trial enrolling patients from multiple clinical centers.

chimeric antigen receptor (car) t cell therapy has proven effective in treating b cell malignancies. however, the application itself is still limited by the high cost and long preparation time which often do not meet the urgent need of patients. in addition, some patients may suffer from long-term immunosuppression caused by tumor microenvironment or after radiotherapy and chemotherapy, resulting in exhaustion, aging and functional defects of the autologous t cells, which will eventually affect the quality of the car-t cells and affect the clinical efficacy. the 4scar19u t cells are genetically engineered and manufactured in bulk amount that can be supplied off-the-shelf without being custom made from individual patients. the immediate availability of the car-t cells makes clinical treatment convenient and timely for rapid progressing disease or for the highly immune suppressed patients. this application can be time- and cost-effective. this novel approach may also overcome problems of functionally defective autologous t cells. the purpose of this clinical trial is to assess the feasibility, safety and efficacy of the 4scar19u t cell product in hematological malignancies. another goal of the study is to learn more about the function of this novel product and its persistence in the patients

Eligibility criteria:
inclusion criteria: 1. age older than 6 months. 2. primary b cell surface expression of cd19. 3. the kps score over 80 points, and survival time is more than 1 month. 4. greater than hgb 80 g/l. 5. no contraindications to blood cell collection. exclusion criteria: 1. accompanied with other active diseases, and difficult to assess response after treatment. 2. bacterial, fungal, or viral infection, unable to control. 3. living with hiv. 4. active hbv or hcv infection. 5. pregnant and nursing mothers. 6. under systemic steroid treatment within a week of the treatment. 7. prior failed car-t treatment.

Keywords: universal car-t cd19 b-all pmbcl cns-bcl bcl